Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Lantheus teams up with Cerevast in retinal vein occlusion  Seeking Alpha

Lantheus Holdings (LNTH -0.9%) will collaborate with Cerevast Medical on a treatment for retinal vein occlusion (RVO), a common cause of vision loss due to ...

Retinal Vein Occlusion - Pipeline Insight, 2019 - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Retinal Vein Occlusion - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Therapeutics for macular edema due to retinal vein occlusion | Clinical Ophthalmology  MD Linx

Ophthalmology Article: Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal ...

Retinal vein occlusion and blood HDL cholesterol | American Journal of Ophthalmology  MD Linx

Internal Medicine Article: Retinal vein occlusion is associated with low blood high-density lipoprotein cholesterol: A nationwide cohort study.

Global Retinal Vein Occlusion Therapeutics Market 2019: Dominant Players Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  Global Industry Journal

Retinal Vein Occlusion Therapeutics ” Global Market 2019: Competitive Approach, Fair Extraordinary Growth & Standardization Towards 2024. From the ocean ...

Retinal Vein Occlusion Market Analysis & Trends to 2025| Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals  Weekly Wall

Los Angeles, United State, April 10, 2019– The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation ...

Retinal Vein Occlusion Therapeutics Market Research Study including Growth Factors, Types and Application by regions from 2019 to 2023  Current News Magazine

Compare the Retinal Vein Occlusion Therapeutics Market with expected revenue in next Five-Year. The Global Retinal Vein Occlusion Therapeutics Market are ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Global Retinal Vein Occlusion Therapeutics Market Insights Report 2019-2024: Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  Industry News Daily

The global “Retinal Vein Occlusion Therapeutics Market” report provides a complete bunch of all-inclusive essential information related to the global Retinal ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Global Retinal Vein Occlusion Therapeutics Market Outlook 2019-2025-Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  Times of Market

The “Retinal Vein Occlusion Therapeutics“Market report contains wide-ranging statistical surveying for Retinal Vein Occlusion Therapeutics which empowers the ...

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article · Related *content* · Metrics ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Global Retinal Vein Occlusion Market Research Report - Forcast To 2023  Market News Biz

Introduction Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

FDA accepts Outlook Therapeutics' IND for ONS-5010  Seeking Alpha

The FDA accepts Outlook Therapeutics' (OTLK) IND application for ONS-5010, an innovative monoclonal antibody (mAb) therapeutic product candidate being ...

Global Retinal Vein Occlusion Therapeutics Market | Trends, Forecast and Analysis (2019-2024).  Business Gazette

Global Retinal Vein Occlusion Therapeutics Market Overview, Strategies, Development, Regulations and pin-point Analysis for changing competitive dynamics.

Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Port Delivery System reduces neovascular AMD treatment burden  medwireNews

medwireNews: The Port Delivery System (PDS) with ranibizumab has the potential to reduce the burden of treatment for patients with neovascular.

Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?  Nasdaq

Shares of Aerie Pharmaceuticals, Inc . AERI have rallied 22.4% in the year so far, outperforming 15.3% growth registered by the industry . The FDA.

What does Novartis' eye business envision without Alcon? Digital M&A, for one thing  FiercePharma

Novartis is “actively evaluating” collaboration and M&A opportunities in several potential ophthalmic digital therapeutics, says Novartis Ophthalmology head ...

2019-2023 Global Retinal Vein Occlusion Treatment Market Analysis, Key Players, Trends, Drivers, Shares  Mcallen Post

Global Retinal Vein Occlusion Treatment Market report conveys detail information and strategies of the top key players in the industry. The report also gives a ...

Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound?  Nasdaq

It has been about a month since the las t earnings report for Aerie Pharmaceuticals (AERI). Shares have lost about 2.9% in that time frame,.

Lantheus partners with Cerevast for new eye care application using Microbubbles  Compelo

Lantheus has collaborated with Cerevast Medical for treating retinal vein occlusion (RVO), a common cause of vision loss across the world.

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)  GlobeNewswire

... -- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety ...

Macular Edema Treatment Market Size Archives  TechnoBleak

Macular Edema Treatment Market 2018 Opportunities, Competition from Opponents, Dynamics, Demand, Challenge and Risk and Forecast to 2026.

Allergan to resume marketing of macular edema treatment  Korea Biomedical Review

Allergan Korea said Tuesday that it has started re-marketing Ozurdex (ingredient: dexamethasone), a steroid eye implant for macular edema.

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

CF Patients at Higher Risk for Retinal Vein Occlusions, Case Report Says  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Global Retinal Vein Occlusion Therapeutics Market 2018: Countries, Industry Size, Challenges, Drivers and Technology Forecast to 2023  Washington DC Herald

Retinal Vein Occlusion Therapeutics Market Report will review upcoming market trends with technology advancement, development planning and production ...

Global Retinal Vein Occlusion Therapeutics Market Study 2019-2025: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Crypto News Today

This report analyzes the Global Retinal Vein Occlusion Therapeutics market size (production, value, capacity and consumption) in key regions like North ...

Macular Edema Treatment Market trends Archives  Business Herald

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an ...

Rising Prevalence of Retinal Diseases Will Support the Growth of Intravitreal (IVT) Injectables Market  New Daily Herald

Rising Prevalence of Retinal Diseases Will Support the Growth of Intravitreal (IVT) Injectables Market. Vitreo-retinal disease has been a major cause of ...

Clearside Bio's Xipere flunks late-stage retinal vein occlusion study; shares down 27% premarket  Seeking Alpha

Thinly traded micro cap Clearside Biomedical (CLSD) is down 27% premarket on light volume in response to its announcement that a Phase 3 clinical trial, SA.

Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights  PRNewswire

PALO ALTO, Calif., March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel ...

Macular Edema Treatment Market  TechZiffy

Macular Edema Treatment Market 2026: Top Companies, Regional Growth Overview and Growth Factors Details by Regions, Types and Applications.

Worldwide Retinal Vein Occlusion Therapeutics Market Research Report Contains Industry Dynamics: Manufacturers Segment Analysis and Trend Prediction to 2023  Washington DC Herald

The Retinal Vein Occlusion Therapeutics Market report offers an unbiased and complete analysis of the on-going trends, opportunities/ high development areas, ...

Global Retinal Vein Occlusion Treatment Market 2019-2023| Strong Pipeline and Recent Drug Approvals to Boost Demand | Technavio  Business Wire

The global retinal vein occlusion treatment market 2019-2023 is expected to post a CAGR of over 9% during the forecast period, according to Technavio.

H.C. Wainwright Sticks to Their Buy Rating for Alimera (ALIM)  Analyst Ratings

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM – Research Report), with a price target of $2.75.

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Retinal Vein Occlusion Therapeutics Market 2019-2023: Global Size, Share, Emerging Trends, Demand, Revenue and Forecasts Research  IFLCARS

Report Name: “Global Retinal Vein Occlusion Therapeutics Market Growth 2019-2023”. The Global Retinal Vein Occlusion Therapeutics market includes ...

Vascular Endothelial Growth Factor B Market | Global Research Insight 2018-2023  TheCells

Global Vascular Endothelial Growth Factor B Insight. Get industry insights and important projections for the market in upcoming quarters with the Global Vascular ...

Specialist shares key messages of Euretina guidelines for management of RVO  Healio

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, ...

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Global Vascular Endothelial Growth Factor B Market 2019 – Alteogen Inc, CSL Ltd, Eli Lilly and Company, Formycon AG, Regeneron Pharmaceuticals Inc  Biz Trends 24

The analysis on the Vascular Endothelial Growth Factor B Market is a thorough study that offers a select combination of skillful market realities. The study shows ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Widefield Imaging Systems market: Supply-Demand, Industry Research and End User Analysis, Outlook 2025 – Key Players are Clarity Medical Systems, Inc., Heidelberg Engineering, Visunex Medical Systems, Inc., CenterVue Optos, ZEISS Group, Daytona  Spaceflight News

Widefield Imaging Systems market: Supply-Demand, Industry Research and End User Analysis, Outlook 2025 – Key Players are Clarity Medical Systems, Inc., ...

Vascular Endothelial Growth Factor B | Global Market Detailed Study 2018-2023  SteerFeed

A research report on “Global Vascular Endothelial Growth Factor B Market 2018 Industry Research Report” is being published by Researchunt.com. This is a key ...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Arteriovenous malformation of the iris  The BMJ

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3699 (Published 20 September 2018) Cite this as: BMJ 2018;362:k3699. Article · Related *content* · Metrics ...

Global Placenta Growth Factor Market 2019 Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd  Industry News Daily

The report on the Global Placenta Growth Factor Market offers complete data on the Placenta Growth Factor market. Components, for example, main players, ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

IND application accepted for Aerie's AR-1105  Healio

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Kodiak's investigational anti-VEGF yields positive results  Healio

Kodiak Sciences' drug candidate KSI-301 improved vision, anatomy or both in eight of nine patients with severe diabetic macular edema in a phase 1a trial, ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Catheter complications . . . and other stories  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l1045 (Published 14 March 2019) Cite this as: BMJ 2019;364:l1045. Article · Related *content* · Metrics ...

SCORE2 subanalysis: Visual gains made after treatment switch  Healio

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to ...

FDA hits Regeneron with CRL for Eylea syringe  BioPharma Dive

The Food and Drug Administration issued a Complete Response Letter to Regeneron Pharmaceuticals over its pre-filled syringe for the company's eye drug ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine ...

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVES:Several imaging modalities have been developed to characterize ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Four Year Analysis Reports Uptick in Aflibercept Use, Decrease in Ranibizumab  MD Magazine

After analyzing 57925 injections administered 2013 and 2017, investigators observed an increase in aflibercept use, with a reciprocal decline in ranibizumab ...

Retinal Vein Occlusion Therapeutics Market to Reflect Steady Growth Rate by 2021 | Kentucky Breaking News Updates  Kentucky Journal 24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron's Eylea at Two Years  BioSpace

With *fresh* two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of ...

FDA accepts Clearside's NDA for Xipere suprachoroidal injection  Healio

The FDA has accepted a new drug application for Xipere suprachoroidal injection for the treatment of macular edema associated with uveitis, according to a ...

Steven Yeh, MD: The Promise of Suprachoroidal Injections  MD Magazine

The director of the Section of Uveitis and Vasculitis at Emory University spoke about the potential of this novel delivery method in conditions such as uveitis and ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

FDA to Review Injection Treatment for Diabetic Retinopathy  Pharmacy Times

The FDA has accepted for review Regeneron Pharmaceuticals' supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Global Retinal Vein Occlusion – Pipeline Insight, 2019  Redfield Report

Report Titled “Retinal Vein Occlusion – Pipeline Insight, 2019” provides product and API manufacturers' details across the globe along with the location.

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

High-Dose ITVA Found Considered Safe, Cost-Effective Alternative to Anti-VEGF  MD Magazine

A new study finds high-dose intravitreal triamcinolone acetonide is a safe alternative to anti-vascular endothelial growth factor, a finding that is welcome news for ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of ...

FEMTOprint develops glass-based puncture tool for retinal vein cannulation  Industrial Laser Solutions Magazine

A collaboration in Switzerland has developed a challenging passive compliant tool for retinal vein occlusion (RVO).

» Load more